ArticleObesity science & practice2026
The Human Monoacylglycerol Acyltransferase 2 Inhibitor VB-85387 Is Associated With Weight Loss in Mice With Obesity.
Article in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD.Journal of lipid research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: GLP-1 therapies for obesity are limited by side effects and weight regain is common after treatment ends. Therefore, alternative treatments with new mechanisms are needed for sustained weight loss. Human MOGAT2 regulates triglyceride metabolism and its inhibition reduces weight in people with obesity, making MOGAT2 a promising target for obesity therapy. Objective: This study evaluated the therapeutic potential of the VB-85387 MOGAT2 inhibitor for weight loss. Methods: High throughput screening was used to identify human MOGAT2 inhibitors. Diet-induced mice with obesity were treated with VB-85387 for 7 days. Body weight, food intake, blood and liver lipid and hormone levels were assessed. Glucose tolerance and insulin sensitivity were evaluated via oral glucose tolerance and hyperinsulaemic-euglycaemic clamp tests. Gene expression of PPARα and SREBP target genes was measured using Results: High throughput screening identified VB-85387 as a highly potent and selective human MOGAT2 inhibitor. Mice with obesity treated with VB-85387 experienced weight loss, reduced food intake, improved glucose tolerance, and enhanced insulin sensitivity. Treatment decreased liver triglyceride levels and increased GLP-1 concentrations. Conclusion: VB-85387 serves as a starting point for medicinal chemistry lead optimization. Weight loss may be attributed to PPARα activation and a sustained elevation in GLP-1 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.